LAKE FOREST, Ill., Feb. 3, 2011 /PRNewswire/ — Hospira, Inc.
(NYSE:
HSP), the world leader in generic injectable pharmaceuticals,
today announced U.S. Food and Drug Administration (FDA) approval of
Topotecan Injection, the first solution formulation of the oncology
drug approved in the United States. The medication is a generic
version of Hycamtin®, which had 2010 U.S. sales of more than
$140 million. Hospira’s topotecan is indicated for treatment of
small cell lung cancer (SCLC) sensitive disease after failure of
first-line chemotherapy.  

The solution formulation of topotecan, with a concentration of 4
mg/4 ml, is designed to improve caregiver convenience and safety,
and Hospira expects to launch the product by the end of
February.

“Hospira’s solution version of topotecan expands our portfolio
of value-added generics,” said Thomas Moore, president, U.S.,
Hospira. “We’re excited to offer the medical community access to a
lower-cost, more convenient version of this key oncolytic.”

Hospira’s specialty injectable pharmaceuticals (SIP) offering
includes approximately 200 generic injectable drugs in many dosages
and formulations. In addition, many of its products are
available in popular differentiated presentations, several of which
are proprietary, such as ADD-Vantage™ drug delivery system
and iSecure™ prefilled syringes. Therapeutic segments
include analgesia, anesthesia, anti-infectives, cardiovascular,
oncology, emergency and other areas. Hospira also has robust
pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness™.
As the world leader in specialty generic injectable
pharmaceuticals, Hospira offers one of the broadest portfolios of
generic acute-care and oncology injectables, as

‘/>”/>

SOURCE